VIVUS is a biopharmaceutical company that develops and commercializes innovative therapies to address unmet medical needs. The company's lead product, Qsymia, is approved in the United States and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. VIVUS is committed to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. The company has a robust pipeline of investigational therapies in clinical and preclinical development for the treatment of pulmonary arterial hypertension, diabetic nephropathy, and other serious diseases.